文献速递慢性肾脏病肾小球疾病

PROPKD评分在TEMPO试验中富集快速进展ADPKD患者的价值

Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial.
PubMed 文献 · Nephrol Dial Transplant · 2018-01-01

本研究对TEMPO3/4试验中770名基因分型的常染色体显性多囊肾病(ADPKD)患者进行事后分析,计算749名突变阳性者的PROPKD评分并分为低、中、高风险组。结果显示高风险组身高校正总肾脏体积(TKV)更高且增长更快,安慰剂组eGFR下降速率随风险升高而增加;托伐他汀在 intermediate 和 high 风险组显著减缓eGFR下降,低风险组无差异。结论支持PROPKD评分可用于富集快速进展患者以提高试验效率。

要点

  • PROPKD评分可区分ADPKD进展风险,高风险组TKV更高且增长更快。
  • 托伐他汀显著减缓中、高风险组eGFR下降,低风险组无效。
  • 排除低风险患者可提高托伐他汀对eGFR下降的治疗效果。

核心结论

  • PROPKD评分在TEMPO试验基因分型亚组中具有预后价值,可用于富集快速进展的ADPKD患者。

研究设计与样本

  • TEMPO3/4试验的事后分析,对770名受试者筛查PKD1和PKD2突变,在749名突变阳性者中计算PROPKD评分。

主要发现

  • PROPKD评分在749名受试者中计算(低风险=132,中风险=344,高风险=273),年龄与风险呈负相关(低风险=43.6岁,中风险=39.5岁,高风险=36.2岁;P<0.001)。
  • 高风险组身高校正总肾脏体积(TKV)及TKV增长率显著更高。
  • 基线肾功能在各风险组相似,但安慰剂组eGFR下降速率从低风险到高风险显著增加。
  • 托伐他汀减缓eGFR下降在中风险组(托伐他汀=-2.34 vs 安慰剂=-3.33 mL/min/1.73 m2/年;P=0.008)和高风险组(托伐他汀=-2.74 vs 安慰剂=-3.94 mL/min/1.73 m2/年;P=0.002)显著,低风险组无差异(托伐他汀=-2.35 vs 安慰剂=-2.50 mL/min/1.73 m2/年;P=0.72)。
  • 排除低风险受试者后,托伐他汀对eGFR下降的治疗效果表观上改善。

关键数值与推荐

  • PROPKD评分计算:男性1分;35岁前高血压2分;35岁前首次泌尿事件2分;非截短PKD1突变2分;截短PKD1突变4分。
  • 风险分组:低风险0-3分,中风险4-6分,高风险7-9分。

临床怎么用

  • 临床可应用PROPKD评分对ADPKD患者进行风险分层,识别快速进展者以加强监测和干预。
  • 未来临床试验可富集高风险患者以提高终点敏感性并降低成本。

局限性

  • 本研究为TEMPO3/4试验的事后分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The PROPKD score has been proposed to stratify the risk of progression to end-stage renal disease in autosomal dominant polycystic kidney disease (ADPKD) subjects. We aimed to assess its prognostic value in a genotyped subgroup of subjects from the Tolvaptan Phase 3 Efficacy and Safety Study in Autosomal Dominant Polycystic Kidney Disease (TEMPO3/4) trial. METHODS: In the post hoc analysis, PKD1 and PKD2 were screened in 770 subjects and the PROPKD score was calculated in mutation-positive subjects (male: 1 point; hypertension <35 years: 2 points; first urologic event <35 years: 2 points; nontruncating PKD1 mutation: 2 points; truncating PKD1 mutation: 4 points). Subjects were classified into low-risk (LR; 0-3 points), intermediate-risk (IR; 4-6 points) and high-risk (HR; 7-9 points) groups. RESULTS: The PROPKD score was calculated in 749 subjects (LR = 132, IR = 344 and HR = 273); age was inversely related to risk (LR = 43.6 years, IR = 39.5 years, HR = 36.2 years; P < 0.001). Subjects from the HR group had significantly higher height-adjusted total kidney volume (TKV) and rates of TKV growth. While baseline renal function was similar across all risk groups, the rate of estimated glomerular filtration rate (eGFR) decline significantly increased from LR to HR in the placebo group. Tolvaptan treatment effectiveness to reduce TKV growth was similar in all three risk categories. While tolvaptan significantly slowed eGFR decline in the IR (tolvaptan = -2.34 versus placebo = -3.33 mL/min/1.73 m2/year; P = 0.008) and HR groups (tolvaptan = -2.74 versus placebo = -3.94 mL/min/1.73 m2/year; P = 0.002), there was no difference in the LR group (tolvaptan = -2.35 versus placebo = -2.50 mL/min/1.73 m2/year; P = 0.72). Excluding the LR subjects from the analysis improved the apparent treatment effect of tolvaptan on eGFR decline. CONCLUSION: This study confirms the prognostic value of the PROPKD score and suggests that it could reduce costs and enhance endpoint sensitivity by enriching future study populations for rapidly progressing ADPKD subjects.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Cornec-Le Gall E, Blais JD, Irazabal MV, et al. Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial. Nephrol Dial Transplant. 2018. PMID: 28992127. doi:10.1093/ndt/gfx188

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。